Partial Epilepsy or partial seizure is a type of seizure associated with epilepsy. Epilepsy is a chronic disorder that causes unprovoked, recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. Epilepsy is categorized as a chronic disease of the brain and continues to affect millions of individuals worldwide. Although the prevalence of epilepsy is marginally higher in men compared to women, it affects individuals from all age groups. The prevalence of focal seizures is higher than that of generalized seizures in both, children as well as adults. The prevalence of epileptic seizures is higher in low to middle-income countries due to which, the demand for epileptic seizure treatment is high from developing regions. Some of the major factors responsible for the high prevalence of epileptic seizures in developing regions include acute symptomatic seizures, misdiagnosis, and lack of advanced medical infrastructure.
AdvanceMarketAnalytics has segmented the market of Global Partial Epilepsy market by Type, Application and Region.
On the basis of geography, the market of Partial Epilepsy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Technological Advancements in the Field of Medical Science
Spurt Witnessed in Epilepsy Cases, Geriatric Population Diagnosed with the Partial Epilepsy, Rise in the Number of Road Accidents in Developed Economies and Spike in Neurological Disorders such as Depression and Parkinsonís
Development of Drugs for the Treatment of Seizures Caused by Epilepsy
- Expiration of Patented Drugs such as BRIVACT is Projected to Impede the Market Growth
In addition to the aforementioned factor, Spurt Witnessed in Epilepsy Cases
is expected to propel the growth of the market over the forecast period.
The global partial epilepsy market is witnessing a rise in competitiveness among the players. In terms of market share, the major players are currently dominating. However, some of the companies are increasing the market presence by securing new contracts and tapping new markets.
The key Players profiled in the study are Eisai Co. Ltd. (Japan),, Novartis AG (Switzerland),, Pfizer Inc. (US),, GW Pharmaceuticals PLC (UK),, Abbott Laboratories (US),, UCB SA (Belgium),, LivaNova PLC (UK),, Medtronic PLC (Ireland),, Johnson & Johnson Services Inc. (US),, GlaxoSmithKline PLC (UK), and and NeuroPace Inc. (US).. A lot of United States and United Kingdom players are profiled in the research study indicating a strong market dependence.